Thermo Fisher Scientific said it will invest an additional $2 billion in the United States over the next four years. These additional investments to the company’s American manufacturing capacity are meant to support the U.S. healthcare supply chain.
The $2 billion investment over the next four years includes:
- $1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations
- Complemented by $500 million in R&D focused on innovation
“Thermo Fisher’s commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. Thermo Fisher is proud to serve as a growth engine for the American economy,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.”
This investment builds on Thermo Fisher’s foundation in U.S. manufacturing and innovation. The company has 64 U.S. manufacturing operations, located in 37 states, making analytical instruments, specialty diagnostics and life sciences solutions, as well as providing contract development and manufacturing services for pharmaceutical innovators.
Since 2017, Thermo Fisher has more than doubled in size—from $21 billion in revenue and 28,000 U.S. employees to $43 billion in revenue and more than 50,000 U.S. employees today. The company also invests $1 billion annually in R&D in the U.S. Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.